Figure 6 | Scientific Reports

Figure 6

From: HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice

Figure 6

Mutation frequency at the potential DCV-binding sites on NS5A. (a,b) Frequency of mutations at the residues spanning amino acids 28–40 including the PxxPxxP motif at the downstream of the N-terminal ER membrane-anchoring amphipathic α-helix (AH; aa 1–27), and the two residues C92 and Y93 known to confer DCV resistance in HCV GT2a. Shown are the NS5A polymorphism and DCV RAV emergence-suppressing effect of HA1077 in mice with HCV rebound (a) or in mice with undetectable serum HCV titers (b) after oral administration of DCV or DCV plus HA1077 for 27 days. *P < 0.05; **P < 0.01; by unpaired two-tailed Student’s t-test. ND, not detected.

Back to article page